Engineered Aspergillus Strain for High-Yield Cyclic Tripeptide Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods yield low amounts of the cyclic tripeptides JBIR-15, aspochracin, and sclerotiotide C, and there is a lack of research on their biological activities, limiting their potential applications in pharmaceuticals.
Innovation Solution
An engineered strain of Aspergillus sp. L14-OE::laeA2 is created by overexpressing the global regulatory factor LaeA in the wild-type Aspergillus niger L14, using PCR, recombinant plasmid construction, and Agrobacterium-mediated fungal transformation to enhance production of these compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional biosynthesis methods are used to produce cyclic tripeptides, then the production process is simple, but the yield is low
Solution Approach 1:
The patent applies parameter changes by overexpressing the LaeA regulatory gene in the Aspergillus niger strain, thereby changing the expression level parameter of biosynthetic genes. This leads to increased production yield of cyclic tripeptides (JBIR-15, aspochracin, and sclerotiotide C) while maintaining the basic fungal fermentation system, thus resolving the contradiction between yield and system complexity
Solution Approach 2:
The patent uses a recombinant plasmid (pCAMBIA-1301) as a copy carrier to introduce and overexpress the LaeA gene in the fungal strain. This plasmid copying mechanism enables enhanced biosynthesis of cyclic tripeptides without fundamentally redesigning the entire fermentation system, thereby improving yield while controlling system complexity
2Quantity of substance
If genome mining strategies are applied to activate silent biosynthetic gene clusters, then novel compounds can be discovered, but the production yield remains limited
Solution Approach 1:
The patent extracts and isolates the LaeA regulatory gene from the Aspergillus niger genome and places it under the control of a strong constitutive promoter (Ptet) in the recombinant plasmid. This extraction and overexpression of the key regulatory factor simplifies the complex gene regulation network, enabling high-level production of cyclic tripeptides without needing to reconfigure the entire biosynthetic pathway
Solution Approach 2:
The patent performs preliminary action by pre-introducing and overexpressing the LaeA gene in the fungal strain before conducting the fermentation process. This preliminary genetic modification ensures that the biosynthetic gene clusters are activated and ready for high-yield production of cyclic tripeptides, resolving the limitation of low yield despite having the genetic potential
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered strain Aspergillus sp. L14-OE::laeA2 produces JBIR-15, aspochracin, and sclerotiotide C with significantly higher yields, enabling their use in high-yield industrial production and applications in anti-tumor and antioxidant drugs.
Implementation Method 1
Aspergillus sp. L14-OE::laeA2 capable of producing three cyclic tripeptides (JBIR-15, aspochracin, and sclerotiotide C)
Data Source
AI summary
An application method includes: applying an Aspergillus sp. L14-OE::laeA2 in producing cyclic tripeptides. In the cyclic tripeptides obtained by separating and purifying a fermented product of the Aspergillus sp. L14-OE::laeA2, a yield of aspochracin is 175 mg/L, a yield of JBIR-15 is 100 mg/L, and a yield of sclerotiotide C is 25 mg/L. The yields of the compounds are significantly higher than those reported in other literature, and a separation process of obtaining the compounds is simple and economical. The cyclic tripeptides may be used to prepare drugs with antifungal activity and antioxidants activity, and for inhibiting activity of tumor cells and anti-tumor drugs. At a concentration of 10 μM, the JBIR-15 has an inhibition rate of 11.78% on a human hepatocellular carcinoma cell line (Hep-G2), and the sclerotiotide C has an inhibition rate of 21.09% on a human hepatocellular carcinoma cell line (Hep-G2).